(R) -Zunsemetinib

(R) -Zunsemetinib is the isomer of Zunsemetinib (HY-139553), and can be used as an experimental control. Zunsemetinib (CDD-450) is an orally active and selective p38α mitogen-activated protein kinase-activated protein kinase 2 (MK2) pathway inhibitor. Zunsemetinib can be used for the research of immuno-inflammatory diseases[1].

Product Specifications

CAS Number

[1640282-44-5]

Product Name Alternative

(R) -ATI-450; (R) -CDD-450

UNSPSC

12352005

Target

Drug Isomer

Type

Reference compound

Related Pathways

Others

Applications

COVID-19-immunoregulation

Field of Research

Inflammation/Immunology

Assay Protocol

https://www.medchemexpress.com/r-zunsemetinib.html

Purity

97.84

Solubility

DMSO : 50 mg/mL (ultrasonic)

Smiles

FC1=CC(F)=CN=C1COC2=C(Cl)C(N(C3=CC(C4=NC(C(C)(C)O)=NC=C4)=NC=C3C)C(C)=C2)=O

Molecular Formula

C25H22ClF2N5O3

Molecular Weight

513.92

References & Citations

[1]Zunsemetinib (ATI-450) – Investigational oral MK2 pathway inhibitor|[2]Aclaris Therapeutics Announces ATI-450 (MK2 pathway Inhibitor) publication in Journal of Experimental Medicine|[3]Wang C, et al. Selective inhibition of the p38α MAPK-MK2 axis inhibits inflammatory cues including inflammasome priming signals. J Exp Med. 2018;215 (5) :1315-1325.